Abstract
Previous genome-wide association studies (GWAS) for adiponectin, a complex trait linked to type 2 diabetes and obesity, identified >20 associated loci. However, most loci were identified in populations of European ancestry, and many of the target genes underlying the associations remain unknown. We conducted a multi-ancestry adiponectin GWAS meta-analysis in ≤46,434 individuals from the METSIM cohort and the ADIPOGen and AGEN consortiums. We combined study-specific association summary statistics using a fixed-effects, inverse variance-weighted approach. We identified 22 loci associated with adiponectin (P < 5×10−8), including 15 known and 7 previously unreported loci. Among individuals of European ancestry, GCTA-COJO identified 14 additional distinct signals at the ADIPOQ, CDH13, HCAR1, and ZNF664 loci. Leveraging the multi-ancestry data, FINEMAP + SuSiE identified 46 causal variants (PP>0.9), which also exhibited potential pleiotropy for cardiometabolic traits. To prioritize target genes at associated loci, we propose a combinatorial likelihood scoring formalism (“GPScore”) based on measures derived from 11 gene prioritization strategies and the physical distance to the transcription start site. With “GPScore”, we prioritize the 30 most probable target genes underlying the adiponectin-associated variants in the multi-ancestry analysis, including well-known causal genes (e.g., ADIPOQ, CDH13) and novel genes (e.g., CSF1, RGS17). Functional association networks revealed complex interactions of prioritized genes, their functionally connected genes, and their underlying pathways centered around insulin and adiponectin signaling, indicating an essential role in regulating energy balance in the body, inflammation, coagulation, fibrinolysis, insulin resistance, and diabetes. Overall, our analyses identify and characterize adiponectin association signals and inform experimental interrogation of target genes for adiponectin.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We will make the final summery stat data available upon publication. IN the interim, all of the summary data of the ADIPOGen consortium, AGEN consortium, and METSIM study are publicly available and may be accessed through their respective websites. The code to reproduce the analyses and figures of this paper is available as Jupyter Notebooks at https://github.com/vsarsani/GPScore.
